At the news
? MIXEDIMPACT 6/10 8-K filed Jun 15, 2026 at 07:48 ET
Nano Dimension announced a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics company. The deal values Infinite at $890 million and will result in existing Nano shareholders retaining a minority stake in the combined company, which will be named Infinite Epigenetics (ticker: IEAI). The combined company is expected to have over $400 million in cash at closing, providing runway without additional capital raises.
- Nano Dimension signed a non-binding term sheet to combine with Infinite Epigenetics for a proposed transaction value of $890 million.
- Existing Nano shareholders expected to retain a meaningful minority ownership interest based on a 20% premium to Nano's estimated net cash at closing.
- Combined company expected to have over $400 million in cash at closing and trade on Nasdaq under ticker IEAI.
- Infinite Epigenetics has collected 120,000+ epigenetic samples, operates a CLIA-certified lab through TruDiagnostic, and targets a $90B+ U.S. clinical diagnostics market.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access